shengnuo biotechnology 2021 Annual Report Released! Innovation + medical beauty double layout, committed to new growth
shengnuo biotechnology officially released its 2021 annual report on April 26, 2022. The annual report covers detailed business reports and key data in seven major sectors, including corporate profits, scientific research innovation, business marketing, and industrial chain building. Multiple data indicators reflect Out of the current stable trend of shengnuo biotechnologylogical.
According to the content of the annual report, shengnuo biotechnology will achieve operating income of 387 million yuan in 2021, a year-on-year increase of 2.05%; net profit attributable to the parent will reach 61 million yuan, a year-on-year increase of 2.09%; net profit after deduction will be 58 million yuan, a year-on-year increase of 12.38% ;
Completed three-year steady growth in operating income and net profit attributable to the parent company. During the reporting period, the company’s total assets reached 957 million yuan, a year-on-year increase of 79.43%; the net assets attributable to shareholders of listed companies reached 785 million yuan, a year-on-year increase of 61.32%. During the reporting period, the company’s assets and shareholders’ net assets increased significantly.
In addition to the growth of revenue data and assets, the annual report also focuses on the achievements of shengnuo biotechnologylogical in scientific research and innovation. As one of the few domestic companies that provides high-level peptide drug CDMO services, in 2021, shengnuo biotechnology will provide pharmaceutical research services for more than 40 projects for new drug R&D companies and scientific research institutions, one of which has been approved and entered the commercialization stage, and 10 peptides The innovative drug has entered the clinical trial stage;
in the research and development of generic drugs, it has mastered the large-scale production technology of 15 varieties of APIs, of which 9 varieties have obtained production approvals in China, and 8 varieties have obtained the US DMF record (activation status), and the extended development Eight peptide preparation varieties have obtained 12 domestic production approvals.
The annual report shows that shengnuo biotechnology has made some progress in the fight against the new coronavirus in the past two years. During the reporting period, the company has provided pharmaceutical research services for two innovative drugs for the treatment of COVID-19 from different customers, and one of them has obtained clinical trial approval and is providing clinical sample production services for it.
It is understood that the patent number of this product is: CN202110070935.7, which is a broad-spectrum coronavirus membrane fusion inhibitor, which can be used to prepare pharmaceutical compositions for the prevention and treatment of diseases caused by coronavirus, and its “effective range is particularly wide” It can prevent and treat other coronaviruses including new coronavirus (2019-nCoV) and many other coronaviruses, which is of great significance for domestic epidemic prevention and control.
The annual report also disclosed the matter of “foreign investment”: Chengdu Shengrong Netac, a wholly-owned subsidiary of the company, subscribed for the newly added registered capital of Guangzhou Shengjing Shangmei Biotechnology Co., Ltd. of RMB 4.9 million at RMB 24.5 million, accounting for the total amount of Guangzhou Shengjing after the capital increase.
49% of the share capital. The capital increase agreement has been signed and the capital contribution will be completed on March 11, 2022. According to relevant information, Guangzhou Shengjing’s main business is to provide a full range of peptide medical beauty products and services, and has its own brand products and formulas, and Shengnuo Bio will also provide raw materials for it in the early stage. At present, the domestic peptide medical and beauty industry-related enterprises are mainly in the stage of OEM of cosmetic peptide active ingredients, and there are few terminal beauty products. Sub-fields will also usher in better development.
In addition to the above key information, the annual report also summarizes the three major systems (quality, operation and production), operation and marketing, and industrial chain layout of shengnuo biotechnology, involving the improvement and improvement of many internal management and operation levels. In 2022, shengnuo biotechnology will make breakthroughs in production line upgrading, R&D innovation, marketing network layout, and building high-quality technology and management teams, with a view to promoting the company to grow into a front-end peptide pharmaceutical company.
Disclaimer: This article is for corporate publicity and commercial information, and is only for users’ reference. If users use it as a reference for consumer behavior, Phoenix.com warns users to make prudent decisions.